For the quarter ending 2026-03-31, IBRX made $44,206K in revenue. -$632,782K in net income. Net profit margin of -1431.44%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 44,206 | 38,285 | 32,061 | 26,425 |
| Cost of sales | 238 | 382 | 177 | 136 |
| Research and development-Nonrelated Party | 64,770 | 60,808 | 48,661 | 52,430 |
| Research and development-Related Party | 3,219 | 3,049 | 2,571 | 2,806 |
| Selling, general and administrative-Nonrelated Party | 44,461 | 37,833 | 35,508 | 41,862 |
| Selling, general and administrative-Related Party | 1,309 | 896 | 774 | 476 |
| Impairment of intangible assets | - | 0 | - | - |
| Total operating costs and expenses | 113,997 | 102,968 | 87,691 | 97,710 |
| Loss from operations | -69,791 | -64,683 | -55,630 | -71,285 |
| Interest and investment income, net | 2,314 | 2,298 | 2,067 | 1,153 |
| Change in fair value of warrant liabilities | 295,413 | -30,743 | -14,905 | -3,889 |
| Change in fair value of related-party convertible note-Related Party | -236,625 | -191 | -1,169 | 1,169 |
| Interest expense-Related Party | 14,559 | 14,843 | 15,256 | 15,474 |
| Interest expense related to revenue interest liability | 13,871 | 12,299 | 12,302 | 13,405 |
| Change in fair value of derivative liabilities | 1,108 | -1,400 | 289 | 1,931 |
| Interest expense-Nonrelated Party | 34 | 50 | 26 | 5 |
| Loss on equity method investment | - | 0 | - | - |
| Other expense, net | -5,917 | -1,668 | -187 | -278 |
| Total other expense, net | -562,997 | 2,590 | -11,679 | -21,020 |
| Loss before income taxes and noncontrolling interest | -632,788 | -62,093 | -67,309 | -92,305 |
| Income tax (expense) benefit | 9 | -135 | -35 | 269 |
| Net loss | -632,797 | -61,958 | -67,274 | -92,574 |
| Net loss attributable to noncontrolling interests, net of tax | -15 | -14 | -21 | -19 |
| Net loss attributable to immunitybio common stockholders | -632,782 | -61,944 | -67,253 | -92,555 |
| Basic EPS | -0.62 | -0.062 | -0.07 | -0.1 |
| Diluted EPS | -0.62 | -0.062 | -0.07 | -0.1 |
| Basic Average Shares | 1,026,874,000 | 991,473,000 | 946,601,000 | 888,216,000 |
| Diluted Average Shares | 1,026,874,000 | 991,473,000 | 946,601,000 | 888,216,000 |
ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. (IBRX)